Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BL-B01D1 |
Trade Name | |
Synonyms | BL B01D1|BLB01D1|BMS986507|BMS 986507|BMS-986507 |
Drug Descriptions |
BL-B01D1 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and ERBB3 (HER3) linked to a topoisomerase I inhibitor, which potentially decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 2642). |
DrugClasses | EGFR Antibody 60 HER3 (ERBB3) Antibody 23 |
CAS Registry Number | NA |
NCIT ID | C186670 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BL-B01D1 | BL-B01D1 | 0 | 1 |
BL-B01D1 + Osimertinib | BL-B01D1 Osimertinib | 0 | 1 |
BL-B01D1 + Pembrolizumab | BL-B01D1 Pembrolizumab | 0 | 1 |